Related references
Note: Only part of the references are listed.Identification of compound D2923 as a novel anti-tumor agent targeting CSF1R
Ying-Qiang Liu et al.
ACTA PHARMACOLOGICA SINICA (2018)
Discovery of Potent Irreversible Pan-Fibroblast Growth Factor Receptor (FGFR) Inhibitors
Yuming Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Cutting to the Chase: How Matrix Metalloproteinase-2 Activity Controls Breast-Cancer-to-Bone Metastasis
Marilena Tauro et al.
CANCERS (2018)
2-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors
Xueqiang Li et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors
Ken A. Brameld et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor
Timothy P. S. Perera et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Advances and challenges in targeting FGFR signalling in cancer
Irina S. Babina et al.
NATURE REVIEWS CANCER (2017)
The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
Teresa Helsten et al.
CLINICAL CANCER RESEARCH (2016)
Discovery of [5-Amino-1-(2-methyl-3H-benzimidazol-5-yl)pyrazol-4-yl]-(1H-indol-2-yl)methanone (CH5183284/Debio 1347), An Orally Available and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor
Hirosato Ebiike et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
FGFR as potential target in the treatment of squamous non small cell lung cancer
Marcello Tiseo et al.
CANCER TREATMENT REVIEWS (2015)
Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma
Kay T. Yeung et al.
CLINICAL CANCER RESEARCH (2015)
The Fibroblast Growth Factor signaling pathway
David M. Ornitz et al.
WILEY INTERDISCIPLINARY REVIEWS-DEVELOPMENTAL BIOLOGY (2015)
Targeting matrix metalloproteinases in cancer: Bringing new life to old ideas
Jillian Cathcart et al.
GENES & DISEASES (2015)
Low Prognostic Implication of Fibroblast Growth Factor Family Activation in Triple-negative Breast Cancer Subsets
Hee Jin Lee et al.
ANNALS OF SURGICAL ONCOLOGY (2014)
Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer
N. Cihoric et al.
BRITISH JOURNAL OF CANCER (2014)
New approaches to selectively target cancer-associated matrix metalloproteinase activity
Marilena Tauro et al.
CANCER AND METASTASIS REVIEWS (2014)
Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma
Eric Angevin et al.
CLINICAL CANCER RESEARCH (2013)
AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family
Paul R. Gavine et al.
CANCER RESEARCH (2012)
Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models
Joseph M. Gozgit et al.
MOLECULAR CANCER THERAPEUTICS (2012)
FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor
Vito Guagnano et al.
CANCER DISCOVERY (2012)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models
Ezia Bello et al.
CANCER RESEARCH (2011)
Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease
Nobuyuki Itoh et al.
JOURNAL OF BIOCHEMISTRY (2011)
Acenaphtho[1,2-b]pyrrole-Based Selective Fibroblast Growth Factor Receptors 1 (FGFR1) Inhibitors: Design, Synthesis, and Biological Activity
Zhuo Chen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models
Genshi Zhao et al.
MOLECULAR CANCER THERAPEUTICS (2011)
EGF and bFGF Promote Invasion That Is Modulated by PI3/Akt Kinase and Erk in Vestibular Schwannoma
Katherine J. Blair et al.
OTOLOGY & NEUROTOLOGY (2011)
Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
Jonathan Weiss et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Fibroblast Growth Factor Receptor 1 Promotes Proliferation and Survival via Activation of the Mitogen-Activated Protein Kinase Pathway in Bladder Cancer
Darren C. Tomlinson et al.
CANCER RESEARCH (2009)
BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy
Frank Hilberg et al.
CANCER RESEARCH (2008)
FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas
Jorge Sergio Reis-Filho et al.
CLINICAL CANCER RESEARCH (2006)
Correlation of basic fibroblast growth factor expression with the invasion and the prognosis of oral squamous cell carcinoma
T Hase et al.
JOURNAL OF ORAL PATHOLOGY & MEDICINE (2006)
Mouse models of breast cancer metastasis
Anna Fantozzi et al.
BREAST CANCER RESEARCH (2006)
Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis
M Presta et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2005)
Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening
TA Halgren et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Site-specific human breast cancer (MDA-MB-231) metastases in nude rats:: Model characterisation and in vivo effects of ibandronate on tumour growth
M Neudert et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Cancer therapy - Matrix metalloproteinase inhibitors and cancer: Trials and tribulations
LM Coussens et al.
SCIENCE (2002)
Share Paper
